Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.

Published on Jun 30, 2020in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.20.00434
Alberto Dalla Volta7
Estimated H-index: 7
(University of Brescia),
Gherardo Mazziotti55
Estimated H-index: 55
(Humanitas University)
+ 5 AuthorsAlfredo Berruti66
Estimated H-index: 66
(University of Brescia)
Sources
Abstract
📖 Papers frequently viewed together
1 Citations
31 Citations
References0
Newest
Cited By2
Newest
#1Carlotta PalumboH-Index: 6
#2Alessandro Antonelli (University of Brescia)H-Index: 30
Last. Alfredo Berruti (University of Brescia)H-Index: 66
view all 13 authors...
BACKGROUND Luteinizing hormone-releasing hormone (LHRH)-agonists in prostate cancer (PCa) patients induce sarcopenic obesity. The effect of LHRH-antagonist on body composition has never been explored. We evaluated changes in fat (FBM) and lean body mass (LBM) in PCa patients undergoing Degarelix. METHODS This is a single-center prospective study, enrolling 29 non-metastatic PCa patients eligible to LHRH-antagonist from 2017 to 2019. All patients received monthly subcutaneous injection of Degarel...
1 CitationsSource
#1Anna Maria Formenti (UniSR: Vita-Salute San Raffaele University)H-Index: 20
#2Alberto Dalla Volta (University of Brescia)H-Index: 7
Last. Andrea Giustina (UniSR: Vita-Salute San Raffaele University)H-Index: 79
view all 5 authors...
Medical treatment of prostate cancer (PC) is multidisciplinary, resulting in prolonged survival. Androgen-deprivation therapy (ADT) can have negative effects on skeletal metabolism, particularly if combined with glucocorticoids. We discuss the pathophysiology and effects of ADT and glucocorticoids on skeletal endpoints, as well as the awareness and management of bone fragility. Coadministration of glucocorticoids is necessary with abiraterone because this causes a novel acquired form of 17-hydro...
2 CitationsSource